Insilico Medicine Lands $2.5 Billion Deal With CDMO Leader Bora in Another Commercialization Breakthrough

A clinical-stage biotech company powered by generative artificial intelligence (AI), Insilico Medicine, and Bora Pharmaceuticals Co., Ltd., a global leader in pharmaceutical manufacturing, have entered into a strategic collaboration alliance. This alliance will be built upon an extensive, multi-faceted cooperation framework, with specific collaboration details to be further discussed and formalized through detailed agreements by both parties.

It is reported that if the agreement is fully implemented, the potential total value of this collaboration is expected to exceed $2.5 billion.

The alliance aims to integrate the technological advantages of Insilico Medicine's proprietary Pharma.AI platform in target discovery, molecule generation, and molecule optimization with Bora Pharmaceuticals' professional capabilities in global drug development, manufacturing, quality management, and commercialization. By bridging the AI-enabled R&D system with automation-driven development, manufacturing, and quality execution processes, both parties are poised to jointly pioneer a new generation of drug R&D models, efficiently integrating the design, development, manufacturing, and delivery of novel molecules, accelerating the provision of innovative solutions for unmet medical needs.

Meanwhile, Insilico Medicine plans to assist Bora Pharmaceuticals in enhancing the AI capabilities of its global team, supporting its transformation into a cutting-edge AI-driven organization. For instance, Insilico Medicine will leverage its strengths in AI algorithm development and platform construction to empower Bora Pharmaceuticals with specific solutions across manufacturing, supply chain, distribution, and corporate operations, further enhancing overall efficiency. As the collaboration deepens, Bora Pharmaceuticals and Insilico Medicine will further expand the scope, scale, and operational framework of their partnership.

Furthermore, as part of the alliance collaboration, Insilico Medicine plans to accelerate Bora Pharmaceuticals' transition toward a more AI-driven and automation-driven drug R&D system by providing comprehensive R&D strategic support and end-to-end AI solutions. In the future, both parties will jointly explore application opportunities for AI and automation methods in areas such as development planning, process optimization, pharmaceutical development, manufacturing readiness, and quality systems.

Sheng Baoxi (Bobby Sheng), Founder and Chairman of Bora Group, and CEO of Bora Pharmaceuticals, stated: "Insilico Medicine has demonstrated to the industry that generative AI can efficiently identify novel targets, design new molecules, and advance drug candidates into clinical development, thereby establishing its pioneering position in AI-driven drug discovery through real-world validation. This strategic partnership marks a significant step in Bora Pharmaceuticals' transformation, signaling its evolution from a leading partner in pharmaceutical development and manufacturing into a broader drug innovation ecosystem. By deeply integrating Insilico Medicine's native AI capabilities with Bora Pharmaceuticals' global expertise in formulation, CMC, regulatory submissions, scale-up production, quality management, commercial manufacturing, supply chain, and market promotion, both parties aim to streamline the entire process from R&D discovery to commercialization, creating an integrated solution."

AI is already reshaping the landscape of drug discovery, but its full potential will only be realized when this transformation extends across the entire value chain of development and manufacturing. This involves not merely integrating AI into existing processes, but reimagining entirely new ways to develop, produce, and deliver pharmaceutical products to patients. We are committed to jointly building a scalable and replicable collaborative model to advance highly promising candidate drugs with greater efficiency. This will not only position Bora Pharmaceuticals at the forefront of AI-enabled pharmaceutical development and manufacturing, but also establish a long-term growth platform through the development and commercialization of high-value, proprietary assets.

Dr. Alex Zhavoronkov, Founder, Co-CEO, and Chief Business Officer of Insilico Medicine, stated: "We are delighted to partner with Bora Pharmaceuticals, a forward-looking industry leader with world-class development and manufacturing capabilities and a steadfast commitment to AI-driven innovation. Previously, Insilico Medicine has continuously expanded its presence in the Asia-Pacific market through collaborations with Takeda and SK Biopharm. This partnership with Bora further deepens Insilico Medicine's cutting-edge innovative collaborations in the Asia-Pacific region. Leveraging Insilico Medicine's proprietary, AI-native engine that spans target discovery, molecule generation, and molecular optimization, we look forward to integrating Bora's production, development, and commercialization capabilities to drive broad AI transformation. Starting from this point, both parties will validate the speed, efficiency, and scalability potential of AI-driven drug discovery."

This strategic alliance reflects both parties' shared vision for next-generation biopharmaceutical innovation: Future drug development will increasingly exhibit the characteristics of AI-native design, data richness, and automation-driven processes. Under this emerging model, value derives not only from the discovery and design of innovative molecules but also from transforming high-quality development projects in a smarter and more efficient manner, ultimately advancing them into therapies that benefit patients. Insilico Medicine possesses an AI-driven drug discovery engine validated across multiple disease areas, while Bora Pharmaceuticals has accumulated extensive expertise in drug development, global manufacturing, quality systems, supply chain execution, and commercialization. With complementary strengths, the two companies are poised to jointly accelerate the evolution of innovative biopharmaceutical models.

As an AI-driven biotechnology company, Insilico Medicine is redefining the efficiency of preclinical drug development through its advanced AI and automation platform. While traditional early-stage drug discovery typically takes 2.5 to 4 years, Insilico Medicine requires an average of only 12 to 18 months to advance a project from initiation to the nomination of a preclinical candidate compound. Since 2021, the company has nominated 31 preclinical candidates, 13 of which have received IND approval. The high-speed innovation and consistent delivery enabled by its AI-driven approach provide a core advantage in this collaboration, complementing Bora Pharmaceuticals' scaled-up development and manufacturing capabilities.

As Insilico Medicine continues to expand the practical applications of its technology in drug discovery and life sciences research, it is also continuously enhancing the performance of its AI platform. Leveraging the extensive experience and data accumulated through its training platform, the company has distilled thousands of benchmarks and integrated them into MMAI Gym. Serving as a "trainer" and "benchmarking platform" for scientific AI, MMAI Gym enables institutions to train models with domain-specific reasoning capabilities and rigorously evaluate their performance on real-world tasks, thereby advancing the journey toward "pharmaceutical superintelligence." To date, Human Longevity and Liquid AI have partnered with Insilico Medicine as collaborators of MMAI Gym.

Insilico Medicine is a global pioneer biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery and drive innovation in the life sciences sector, empowering humanity to live longer and healthier lives. On December 30, 2025, the company was listed on the Main Board of The Stock Exchange of Hong Kong Limited, with stock code: 03696.HK.

Leveraging its proprietary Pharma.AI platform and advanced automated biology laboratories, Insilico Medicine is delivering innovative drug solutions for unmet needs in fibrosis, oncology, immunology, pain, obesity, and metabolic disorders. Furthermore, Insilico Medicine continues to expand the application of Pharma.AI into diverse fields, including advanced materials, agriculture, nutritional products, and veterinary medicines.

Bora Pharmaceuticals Co., Ltd. (Taiwan Stock Exchange Code: 6472; U.S. OTCQX Code: BORAY) was established in 2007 as a pharmaceutical services company that has continuously earned the trust of the global pharmaceutical industry, upholding the vision and goal of "contributing to the health of people worldwide" since its inception.

Bora Pharmaceuticals has grown and expanded through a "dual-engine" business model that concurrently advances CDMO services and pharmaceutical development and sales. The company primarily assists pharmaceutical and biotechnology partners in optimizing product development processes, accelerating time-to-market, and scaling up supply to meet the needs of patients worldwide. Bora also focuses on niche markets and rare disease sectors in the United States, committed to enhancing patients' quality of life by strengthening its sales channel capabilities.

By continuously investing in talent, production and sales, and expanding into the biologics sector, Bora Pharmaceuticals consistently drives business upgrading and sustainable development. We remain focused on high quality, high efficiency, and reliability, setting new benchmarks in the pharmaceutical and CDMO industries.